PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 635-643

  Kalinsky, Kevin ^a   Heguy, Adriana ^b   Bhanot, Umeshkumar K ^b   Patil, Sujata ^b   Moynahan, Mary Ellen ^b  

^a NewYork Presbyterian Hospital   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ductal carcinoma in situ; Genetic fingerprinting; Intratumoral heterogeneity; Metastatic breast cancer; PIK3CA mutation

Indexed keywords

AKT1 GENE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; DNA FINGERPRINTING; GENE; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INTRATUMORAL HETEROGENEITY; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PIK3CA GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; DISEASE PROGRESSION; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEW YORK CITY; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 80955181019     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1601-4     Document Type: Article

References (25)

1. JA Engelman J Luo LC Cantley 2006 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev 7 8 606 619 10.1038/nrg1879 1:CAS:528:DC%2BD28XmvFCnu7Y%3D (Pubitemid 44100518)
2. TL Yuan LC Cantley 2008 PI3K pathway alterations in cancer: variations on a theme Oncogene 27 41 5497 5510 10.1038/onc.2008.245 18794884 10.1038/onc.2008.245 1:CAS:528:DC%2BD1cXhtFWiurzI
3. S Loi B Haibe-Kains S Majjaj F Lallemand V Durbecq D Larsimont AM Gonzalez-Angulo L Pusztai WF Symmans A Bardelli P Ellis AN Tutt CE Gillett BT Hennessy GB Mills WA Phillips MJ Piccart TP Speed GA McArthur C Sotiriou 2010 PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Proc Natl Acad Sci USA 107 22 10208 10213 10.1073/pnas.0907011107 20479250 10.1073/pnas.0907011107 1:CAS:528:DC%2BC3cXnslOntb0%3D
4. K Kalinsky LM Jacks A Heguy S Patil M Drobnjak UK Bhanot CV Hedvat TA Traina D Solit W Gerald ME Moynahan 2009 PIK3CA mutation associates with improved outcome in breast cancer Clin Cancer Res 15 16 5049 5059 10.1158/1078-0432.CCR-09-0632 19671852 10.1158/1078-0432.CCR-09-0632 1:CAS:528:DC%2BD1MXpvFeis78%3D
5. HG Russnes HK Vollan OC Lingjaerde A Krasnitz P Lundin B Naume T Sorlie E Borgen IH Rye A Langerod SF Chin AE Teschendorff PJ Stephens S Maner E Schlichting LO Baumbusch R Karesen MP Stratton M Wigler C Caldas A Zetterberg J Hicks AL Borresen-Dale 2010 Genomic architecture characterizes tumor progression paths and fate in breast cancer patients Sci Transl Med 2 38 38ra47 10.1126/scitranslmed.3000611 20592421
6. M Arnedos A Nerurkar P Osin R A'Hern IE Smith M Dowsett 2009 Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 12 1948 1952 10.1093/annonc/mdp234 19570962 10.1093/annonc/mdp234 1:STN:280:DC%2BD1MjntFOjsQ%3D%3D
7. RJ Burcombe A Makris PI Richman FM Daley S Noble M Pittam D Wright SA Allen J Dove GD Wilson 2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 1 147 155 10.1038/sj.bjc.6602256 15611798 10.1038/sj.bjc.6602256 1:CAS:528:DC%2BD2MXhtFSjsr0%3D (Pubitemid 40188448)
8. S Taucher M Rudas M Gnant K Thomanek P Dubsky S Roka T Bachleitner D Kandioler C Wenzel G Steger M Mittlbock R Jakesz 2003 Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy Endocr Relat Cancer 10 1 91 98 12653672 10.1677/erc.0.0100091 1:CAS:528:DC%2BD3sXksVahtLc%3D (Pubitemid 36457240)
9. S Taucher M Rudas RM Mader M Gnant E Sporn P Dubsky S Roka T Bachleitner F Fitzal D Kandioler C Wenzel GG Steger M Mittlbock R Jakesz 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer Breast Cancer Res Treat 82 3 207 213 10.1023/B:BREA.0000004378.15859.51 14703068 10.1023/B:BREA.0000004378.15859.51 1:CAS:528:DC%2BD3sXptVCrurY%3D (Pubitemid 37521977)
10. M Brunelli E Manfrin G Martignoni K Miller A Remo D Reghellin S Bersani S Gobbo A Eccher M Chilosi F Bonetti 2009 Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria Am J Clin Pathol 131 5 678 682 10.1309/AJCP09VUTZWZXBMJ 19369627 10.1309/AJCP09VUTZWZXBMJ
11. LN Harris F You SJ Schnitt A Witkiewicz X Lu D Sgroi PD Ryan SE Come HJ Burstein BA Lesnikoski M Kamma PN Friedman R Gelman JD Iglehart EP Winer 2007 Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer Clin Cancer Res 13 4 1198 1207 10.1158/1078-0432.CCR-06-1304 17317830 10.1158/1078-0432.CCR-06-1304 1:CAS:528:DC%2BD2sXhvF2hsbo%3D (Pubitemid 46424061)
12. J Hurley P Doliny I Reis O Silva C Gomez-Fernandez P Velez G Pauletti JE Powell MD Pegram DJ Slamon 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 12 1831 1838 10.1200/JCO.2005.02.8886 16549824 10.1200/JCO.2005.02.8886 1:CAS:528:DC%2BD28XkvVajt7k%3D (Pubitemid 46638980)
13. EA Mittendorf Y Wu M Scaltriti F Meric-Bernstam KK Hunt S Dawood FJ Esteva AU Buzdar H Chen S Eksambi GN Hortobagyi J Baselga AM Gonzalez-Angulo 2009 Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 23 7381 7388 10.1158/1078-0432.CCR-09-1735 19920100 10.1158/1078-0432.CCR-09-1735 1:CAS:528:DC%2BD1MXhsFSnu7rL
14. WT Barry DN Kernagis HK Dressman RJ Griffis JD Hunter JA Olson JR Marks GS Ginsburg PK Marcom JR Nevins J Geradts MB Datto 2010 Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome J Clin Oncol 28 13 2198 2206 10.1200/JCO.2009.26.7245 20368555 10.1200/JCO.2009.26.7245
15. B Vogelstein ER Fearon SR Hamilton SE Kern AC Preisinger M Leppert Y Nakamura R White AM Smits JL Bos 1988 Genetic alterations during colorectal-tumor development N Engl J Med 319 9 525 532 10.1056/ NEJM198809013190901 2841597 10.1056/NEJM198809013190901 1:STN:280: DyaL1czgt1aqtQ%3D%3D
16. J Dunlap C Le A Shukla J Patterson A Presnell MC Heinrich CL Corless ML Troxell 2010 Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma Breast Cancer Res Treat 120 2 409 418 10.1007/s10549-009-0406-1 19418217 10.1007/s10549-009-0406-1 1:CAS:528:DC%2BC3cXjtlahurw%3D
17. H Li R Zhu L Wang T Zhu Q Li Q Chen H Wang H Zhu 2010 PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast Exp Mol Pathol 88 1 150 155 10.1016/j.yexmp.2009.09.016 19818761 10.1016/j.yexmp.2009.09.016 1:CAS:528:DC%2BC3cXhtlClsL4%3D
18. A Miron M Varadi D Carrasco H Li L Luongo HJ Kim SY Park EY Cho G Lewis S Kehoe JD Iglehart D Dillon DC Allred L Macconaill R Gelman K Polyak 2010 PIK3CA mutations in in situ and invasive breast carcinomas Cancer Res 70 14 5674 5678 10.1158/0008-5472.CAN-08-2660 20551053 10.1158/0008-5472.CAN-08-2660 1:CAS:528:DC%2BC3cXovVantb4%3D
19. J Dupont Jensen AV Laenkholm A Knoop M Ewertz R Bandaru W Liu W Hackl JC Barrett H Gardner 2011 PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer Clin Cancer Res 17 4 667 677 10.1158/1078-0432.CCR-10-1133 20940279 10.1158/1078-0432.CCR-10-1133 1:CAS:528:DC%2BC3MXitVSqtb8%3D
20. M Janakiraman E Vakiani Z Zeng CA Pratilas BS Taylor D Chitale E Halilovic M Wilson K Huberman JC Ricarte Filho Y Persaud DA Levine JA Fagin SC Jhanwar JM Mariadason A Lash M Ladanyi LB Saltz A Heguy PB Paty DB Solit 2010 Genomic and biological characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 14 5901 5911 10.1158/0008-5472.CAN-10-0192 20570890 10.1158/0008-5472.CAN-10-0192 1:CAS:528:DC%2BC3cXovVanu70%3D
21. C Hafner E Lopez-Knowles NM Luis A Toll E Baselga A Fernandez-Casado S Hernandez A Ribe T Mentzel R Stoehr F Hofstaedter M Landthaler T Vogt RM Pujol A Hartmann FX Real 2007 Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern Proc Natl Acad Sci USA 104 33 13450 13454 10.1073/pnas.0705218104 17673550 10.1073/pnas.0705218104 1:CAS:528:DC%2BD2sXps1Kgtbk%3D (Pubitemid 47293965)
22. K Graham X Ge A de Las Morenas A Tripathi CL Rosenberg 2011 Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium Clin Cancer Res 17 2 236 246 10.1158/1078-0432.CCR-10-1369 21059815 10.1158/1078-0432.CCR-10-1369 1:CAS:528:DC%2BC3MXmslyrsQ%3D%3D
23. N Maruyama Y Miyoshi T Taguchi Y Tamaki M Monden S Noguchi 2007 Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 13 2 Pt 1 408 414 17202311 10.1158/1078-0432.CCR-06-0267 1:CAS:528:DC%2BD2sXoslSmtg%3D%3D (Pubitemid 46225343)
24. CM Heaphy JK Griffith M Bisoffi 2009 Mammary field cancerization: molecular evidence and clinical importance Breast Cancer Res Treat 118 2 229 239 10.1007/s10549-009-0504-0 19685287 10.1007/s10549-009-0504-0
25. LV Sequist BA Waltman D Dias-Santagata S Digumarthy AB Turke P Fidias K Bergethon AT Shaw S Gettinger AK Cosper S Akhavanfard RS Heist J Temel JG Christensen JC Wain TJ Lynch K Vernovsky EJ Mark M Lanuti AJ Iafrate M Mino-Kenudson JA Engelman 2011 Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 75 75ra26 10.1126/scitranslmed.3002003 21430269